Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23997297 | 1.00 | LMNA (0.53) | LMNAHTTFEN1MEN1CYP1A2 | |
| SCHEMBL30344937 | 0.88 | LMNA (0.63) | LMNAHTTFEN1MEN1CYP1A2 | |
| SCHEMBL23997413 | 0.88 | LMNA (0.63) | LMNAHTTFEN1MEN1CYP1A2 | |
| SCHEMBL31711487 | 0.87 | LMNA (0.50) | LMNAHTTFEN1MEN1CYP1A2 | |
| SCHEMBL23997216 | 0.87 | LMNA (0.50) | LMNAHTTFEN1MEN1CYP1A2 | |
| SCHEMBL23997296 | 0.85 | LMNA (0.53) | LMNAHTTMEN1CYP1A2KMT2A | |
| SCHEMBL30345095 | 0.85 | LMNA (0.53) | LMNAHTTMEN1CYP1A2KMT2A | |
| SCHEMBL23997344 | 0.85 | LMNA (0.58) | LMNAHTTMEN1CYP1A2KMT2A | |
| SCHEMBL30345067 | 0.85 | LMNA (0.58) | LMNAHTTMEN1CYP1A2KMT2A | |
| SCHEMBL25720691 | 0.83 | LMNA (0.53) | LMNAHTTMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | LMNA 4017/4885HTT 4501/4885FEN1 3654/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | LMNA 4017/4885HTT 4501/4885FEN1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.